Hypocalcemic cardiomyopathy - A rare and reversible entity

Santos, Tiago da Silva; Carvalho, André

doi:10.1016/j.ajem.2021.06.060

Cited by 2 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In most cases, hypocalcemic cardiomyopathy manifests as a treatable cause of heart failure as normalization of calcium concentration could lead to complete recovery of cardiac function ( 3 , 4 , 9 – 12 ). However, prolonged and profound hypocalcemia may cause irreversible myocardial damage and extensive interstitial fibrosis in rare cases, in which complete recovery of cardiac function could not be reached ( 13 , 14 ).…”

Section: Discussionmentioning

confidence: 99%

Hypocalcemic cardiomyopathy: A case report

Wen

Luo

2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Hypocalcemia and its related symptoms are common manifestations in postsurgical hypoparathyroidism, but patients with hypocalcemia manifested as heart failure is rare and few cases are reported in the literature. Here we reported a 58-year-old female with hypoparathyroidism and uncontrolled hypocalcemia after thyroidectomy, presented with acute heart failure, accompanied with enlargement and reduced ejection fraction of left ventricle. She was refractory to guideline-directed medical therapy for heart failure including digitalis and diuretics. However, her symptoms resolved and cardiac function improved dramatically after normalization of serum calcium level. This rare case highlights the pivotal role of calcium in maintaining cardiac function and the importance of treating underlying reversible causes of heart failure. For patients with hypoparathyroidism, it is essential to get standard treatment to avoid development of heart failure and hypocalcemia related syndromes.

show abstract

Section: Discussionmentioning

confidence: 99%

Hypocalcemic cardiomyopathy: A case report

Wen

Luo

2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

Lower Risk of Cardiovascular Events in Adult Patients with Chronic Hypoparathyroidism Treated with rhPTH(1–84): A Retrospective Cohort Study

Ayodele

Berman

et al. 2022

Adv Ther

View full text Add to dashboard Cite

Introduction Patients with chronic hypoparathyroidism are at increased risk of cardiovascular disease. This study evaluated the risk of developing cardiovascular conditions over a period of 5 years in adult patients with chronic hypoparathyroidism treated with recombinant human parathyroid hormone (1–84), rhPTH(1–84), compared with a historical control cohort of patients not treated with rhPTH(1–84). Methods This retrospective cohort study comprised patients with chronic hypoparathyroidism treated with rhPTH(1–84) in the REPLACE (NCT00732615), RELAY (NCT01268098), and RACE (NCT01297309) clinical trials, and controls selected from the IBM ® Explorys electronic medical record database (January 2007–August 2019) who did not receive parathyroid hormone but who had enrollment criteria similar to those for the clinical trials. Cardiovascular outcomes were the first diagnosis of cerebrovascular, coronary artery, peripheral vascular disease, or heart failure during the study period. Results We evaluated 113 adult patients with chronic hypoparathyroidism treated with rhPTH(1–84) and 618 control patients who did not receive rhPTH(1–84). Over the 5-year follow-up period, 3.5% of patients ( n = 4) in the rhPTH(1–84) cohort had a cardiovascular event compared with 16.3% ( n = 101) in the control cohort. Kaplan–Meier analysis demonstrated that patients in the rhPTH(1–84) cohort had lower risk of experiencing a cardiovascular event compared with patients in the control cohort ( P = 0.005). Multivariable analyses adjusted for baseline variables showed that patients in the rhPTH(1–84) cohort had 75% lower risk for a cardiovascular event compared with patients in the control cohort (adjusted hazard ratio, 0.25 [95% CI 0.08–0.81]; P = 0.020). Conclusion Long-term treatment with rhPTH(1–84) was associated with a lower risk of incident cardiovascular conditions compared with conventional therapy in patients with chronic hypoparathyroidism. Previous studies demonstrated that mineral homeostasis was maintained with lower use of calcium and active vitamin D when rhPTH(1–84) was added to conventional therapy. Future studies are needed to understand whether improved regulation of mineral homeostasis conferred by rhPTH(1–84) may provide long-term cardiovascular benefits to patients with chronic hypoparathyroidism. Supplementary Information The online version contains supplementary material available at 10.1007/s12325-022-02198-y.

show abstract

Hypocalcemic cardiomyopathy - A rare and reversible entity

Cited by 2 publications

References 6 publications

Hypocalcemic cardiomyopathy: A case report

Hypocalcemic cardiomyopathy: A case report

Lower Risk of Cardiovascular Events in Adult Patients with Chronic Hypoparathyroidism Treated with rhPTH(1–84): A Retrospective Cohort Study

Contact Info

Product

Resources

About